Seth C. Hopkins

机构：Otsuka (United States), Sumitomo Dainippon Pharma (United States), Ensemble Therapeutics (United States) · ORCID：0000-0003-3999-2281

发表论文 115 篇 · 总被引 2462 次 · h-index 25

代表论文

• Mesostriatal Dopaminergic Circuit Dysfunction in Schizophrenia: A Multimodal Neuromelanin-Sensitive Magnetic Resonance Imaging and [18F]-DOPA Positron Emission Tomography Study (2024 · Biological Psychiatry · 被引 25)
• TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding (2024 · Molecular Metabolism · 被引 23)
• TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner (2023 · Neuropsychopharmacology · 被引 18)
• Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study (2025 · American Journal of Psychiatry · 被引 11)
• Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting (2023 · Translational Psychiatry · 被引 10)
• TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes (2024 · Diabetes Obesity and Metabolism · 被引 7)